Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

Blood

Volumn 121, Issue 8, 2013, Pages 1403-1412

  Rossi, Davide ^a   Rasi, Silvia ^a   Spina, Valeria ^a   Bruscaggin, Alessio ^a   Monti, Sara ^a   Ciardullo, Carmela ^a   Deambrogi, Clara ^a   Khiabanian, Hossein ^b   Serra, Roberto ^a   Bertoni, Francesco ^c   Forconi, Francesco ^d,e   Laurenti, Luca ^f   Marasca, Roberto ^g   Dal Bo, Michele ^h   Rossi, Francesca Maria ^h   Bulian, Pietro ^h   Nomdedeu, Josep ⁱ   Del Poeta, Giovanni ^j   Gattei, Valter ^h   Pasqualucci, Laura ^b,k,l   Rabadan, Raul ^b   Foà, Robin ^m   Dalla Favera, Riccardo ^b,k   Gaidano, Gianluca ^a   more..

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY OF SIENA   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j UNIVERSITY OF ROME TOR VERGATA   (Italy)

^k NewYork Presbyterian Hospital   (United States)

^l UNIVERSITY OF PERUGIA   (Italy)

^m SAPIENZA UNIVERSITY OF ROME   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIRC3 PROTEIN; CYCLOPHOSPHAMIDE; FLUDARABINE; NOTCH1 RECEPTOR; PENTOSTATIN; PROTEIN; PROTEIN P53; RITUXIMAB; SF3B1 PROTEIN; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER TISSUE; CHROMOSOME 11Q; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CLONAL EVOLUTION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETIC MODEL; GENETIC RISK; HUMAN; HUMAN TISSUE; KARYOTYPE; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 84874428346     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-458265     Document Type: Article

References (39)

1. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371(9617):1017-1029. (Pubitemid 351389535)
2. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
3. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lym-phocytic leukemia. N Engl J Med. 2000;343(26):1910-1916. (Pubitemid 32064784)
4. Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia. 2012;26(7):1458-1461.
5. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389-1401.
6. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
7. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012;44(1):47-52.
8. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. 2011;118(26):6904-6908.
9. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497-2506.
10. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012;119(2):521-529.
11. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefrac-toriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012;119(12):2854-2862.
12. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006;24(28):4634-4641. (Pubitemid 46630962)
13. Zenz T, Kröber A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112(8):3322-3329.
14. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391-3401.
15. Kujawski L, Ouillette P, Erba H, et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood. 2008;112(5):1993-2003.
16. Gunnarsson R, Isaksson A, Mansouri M, et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia. 2010;24(1):211-215.
17. Ouillette P, Fossum S, Parkin B, et al. Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res. 2010;16(3):835-847.
18. Gunnarsson R, Mansouri L, Isaksson A, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica. 2011;96(8):1161-1169.
19. Ouillette P, Collins R, Shakhan S, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood. 2011;118(11):3051-3061.
20. Knight SJ, Yau C, Clifford R, et al. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lympho-cytic leukemia. Leukemia. 2012;26(7):1564-1575.
21. Shedden K, Li Y, Ouillette P, Malek SN. Characteristics of chronic lymphocytic leukemia with so-matically acquired mutations in NOTCH1 exon 34. Leukemia. 2012;26(5):1108-1110.
22. Schuh A, Becq J, Humphray S, et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood. 2012;120(20):4191-4196.
23. Efron B, Tibshirani R. Improvements on cross-validation: the. 632-bootstrap method. JASA. 1997;92(4328):548-560.
24. Harrell FE Jr. Regression Modeling Strategies. New York, NY: Springer-Verlag; 2001.
25. Ciampi A, Negassa A, Lou Z. Tree-structured prediction for censored survival data and the Cox model. J Clin Epidemiol. 1995;48(5):675-689.
26. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS, Random survival forests. Ann Appl Stat. 2008;2(3):841-860.
27. Balatti V, Bottoni A, Palamarchuk A, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012;119(2):329-331.
28. Del Giudice I, Rossi D, Chiaretti S, et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haemato-logica. 2012;97(3):437-441.
29. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of flu-darabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088. (Pubitemid 46211313)
30. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV (H) status and immunophenotyping. Leukemia. 2007;21(12):2442-2451. (Pubitemid 350148886)
31. Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia. 2010;24(3):512-520.
32. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-569. (Pubitemid 34438817)
33. Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmuno-therapy. Blood. 2012;119(18):4101-4107.
34. Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 2007;92(9):1242-1245. (Pubitemid 350144184)
35. Laurie CC, Laurie CA, Rice K, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012;44(6):642-650.
36. Jacobs KB, Yeager M, Zhou W, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012;44(6):651-658.
37. Fazi C, Scarfò L, Pecciarini L, et al. General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood. 2011;118(25):6618- 6625.
38. Wiestner A. Emerging role of kinase targeted strategies in chronic lymphocytic leukemia. Blood. 2012;120(24):4684-4691.
39. Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012;30(23):2820-2822.